Lupin Limited, a global pharmaceutical company, announced on Tuesday that the US Food and Drug Administration (FDA) has approved its Abbreviated New Drug Application (ANDA), Arformoterol Tartrate Inhalation Solution 15 mcg (base)/2 ml, Unit-dose Vialsto market a generic equivalent of Sunovion Pharmaceuticals Inc.’s Brovana Inhalation Solution, 15 mcg/2 ml (Sunovion).
Arformoterol Tartrate Inhalation Solution 15 mcg (base)/2 ml, Unit-dose Vials are indicated for the long-term maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Arformoterol Tartrate Inhalation Solution is for use by nebulization only.
